CSSPF Projected Dividend Yield

Circassia Group Plc ( OTCBB : CSSPF )

Circassia Pharmaceuticals is engaged in the specialty respiratory pharmaceutical business. Co. sells its NIOX® asthma management products directly to specialists in the U.S., U.K. and Germany, and other countries via its network of partners. Co. has a collaboration in the U.S. in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the U.S. commercial rights to late-stage COPD product Duaklir®. Co.'s development pipeline includes a range of respiratory medicines. Co.'s principal asthma treatment, Fliveo®, is approved in the U.K. Co.'s pipeline also includes a number of inhaled medicines for COPD, including single and combination dose products.

21 YEAR PERFORMANCE RESULTS